within Pharmacolibrary.Drugs.N_NervousSystem.N01A_AnestheticsGeneral.N01AX03_Ketamine;

model Ketamine_1
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.17,
    Cl = 2.1933333333333332e-05,
    adminDuration = 600,
    adminMass = 2.5 / 1000000,
    adminCount = 1,
    Vd = 0.0031,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.008833333333333334,
    Tlag = 720,
    Vdp = 0.0105,
    k12 = 3.5000000000000004e-05,
    k21 = 3.5000000000000004e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Ketamine_1</td></tr><tr><td>ATC code:</td><td>N01AX03_1</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>2.5</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>3.1</td><td>L</td></tr>
    <tr><td>clearance:</td><td>18.8</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ketamine is a dissociative anesthetic primarily used for anesthesia and analgesia. It acts as an NMDA receptor antagonist and is notable for its use in both human and veterinary medicine. Ketamine has also been researched and used off-label for treatment-resistant depression and acute pain management. It is approved and in clinical use as an anesthetic agent.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters of ketamine after oral administration in healthy adult volunteers.</p><h4>References</h4><ol><li><p>Simons, P, et al., &amp; Dahan, A (2022). . <i>Frontiers in pain research (Lausanne, Switzerland)</i> 3 946486–None. DOI:<a href=\"https://doi.org/10.3389/fpain.2022.946486\">10.3389/fpain.2022.946486</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35899184/\">https://pubmed.ncbi.nlm.nih.gov/35899184</a></p></li><li><p>Fanta, S, et al., &amp; Kalso, E (2015). Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing. <i>European journal of clinical pharmacology</i> 71(4) 441–447. DOI:<a href=\"https://doi.org/10.1007/s00228-015-1826-y\">10.1007/s00228-015-1826-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25724645/\">https://pubmed.ncbi.nlm.nih.gov/25724645</a></p></li><li><p>Dutton, M, et al., &amp; Hermens, DF (2023). Oral ketamine may offer a solution to the ketamine conundrum. <i>Psychopharmacology</i> 240(12) 2483–2497. DOI:<a href=\"https://doi.org/10.1007/s00213-023-06480-x\">10.1007/s00213-023-06480-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37882811/\">https://pubmed.ncbi.nlm.nih.gov/37882811</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N01AX03_1 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Ketamine_1;
